Log in to search using one of your social media accounts:

 

A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma

A systematic review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. The criteria for inclusion of the trials were established before the review. A search of Medline, Embase, and the Cochrane library databases was conducted to identify phase II or III randomized controlled trials (RCTs), reported from January 1, 1994 to May 29, 2016. Relevant conference abstracts, citation lists from the included articles, published guidelines, and on-going clinical trial databases were also searched.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Source Type: research

Related Links:

The Registry of Monoclonal Gammopathies (RMG) collects long-term data on patients with hematological malignancies and is one of the largest registries of its kind in Europe. This non-interventional, observational study analyzed real-world data from 2446 Czech patients from the RMG to provide insights into real-world treatment outcomes in patients with multiple myeloma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Conclusions 18F-FDG PET/CT shows high diagnostic performance in the evaluation of BMI in pediatric HL. BMB should be ideally reserved for patients with 18F-FDG PET/CT presenting doubtful bone marrow findings. Teaser This study investigated the utility of F-18-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in assessing bone marrow involvement (BMI) compared to bone marrow biopsy (BMB) in newly diagnosed pediatric Hodgkin’s lymphoma (HL). 18F-FDG PET/CT shows high diagnostic performance in evaluating BMI in pediatric HL. BMB should be ideally reserved for patients with 18F-...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study aims to identify the characteristics and outcomes of patients with extralymphatic HL. We performed a retrospective single institution study of 341 cases (207 (61%) males and 134 (39%) females) with a median follow-up of 44 months; 55 patients (16%) had extralymphatic disease. The sites were the lung in 29 patients (44%), bone in 22 (33%), liver in 5 (18%) and kidney in 3 (5%). In 46 patients (86%) only one organ was involved, while in 7 patients (13%) extralymphatic disease was present in 2 sites and in 2 patients (3%) in 3 sites. The extralymphatic disease group had a poorer prognosis than the lymphatic group. ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study investigated the utility of F-18-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in assessing bone marrow involvement (BMI) compared to bone marrow biopsy (BMB) in newly diagnosed pediatric Hodgkin ’s lymphoma (HL). 18F-FDG PET/CT shows high diagnostic performance in evaluating BMI in pediatric HL. BMB should be ideally reserved for patients with 18F-FDG PET/CT presenting doubtful bone marrow findings.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
This study aims to identify the characteristics and outcomes of patients with extralymphatic HL. We performed a retrospective single institution study of 341 cases (207 (61%) males and 134 (39%) females) with a median follow-up of 44 months; 55 patients (16%) had extralymphatic disease. The sites were the lung in 29 patients (44%), bone in 22 (33%), liver in 5 (18%) and kidney in 3 (5%). In 46 patients (86%) only one organ was involved, while in 7 patients (13%) extralymphatic disease was present in 2 sites and in 2 patients (3%) in 3 sites.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 3 April 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Sabina Chiaretti, Elias Jabbour, Dieter Hoelzer The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured. The evaluation of minimal residual disease currently represents the most important prognostic indicator, which drives treatment algorithms, which include allogeneic stem cell transplantation (allo-SCT) allocation. Indeed, for high-risk patients, allo-SCT should be pursued as soon as possible,...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This report adds to the pool of cases that reveal associations between use of lenalidomide and increased risk of developing secondary primary high-grade astrocytomas in multiple myeloma. PMID: 29616908 [PubMed - in process]
Source: The Permanente journal - Category: General Medicine Tags: Perm J Source Type: research
Publication date: Available online 5 April 2018 Source:Acta Pharmaceutica Sinica B Author(s): Zijun Zhao, Yu Chen, Ngiambudulu M. Francisco, Yuanqing Zhang, Minhao Wu Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. The whole procedure of CAR-T cell production is not well understood. The CAR-T cell has been used predominantly in the tr...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
Conclusion Patients deemed fit to receive T10-based conditioning for allogeneic stem-cell transplantation to treat high-risk hematologic malignancies had better overall and progression-free survival than those who received T5 with no additional toxicities. Patients should be stratified before conditioning, and those judged fit should receive T10, while the others should consider alternative reduced-intensity conditioning regimens. Micro-Abstract A study evaluating the optimal dose of myeloablation in thiotepa, busulfan, and fludarabine (TBF) conditioning included 29 patients who received TBF conditioning before allogeneic ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion SC Btz is associated with better tolerance; however, IV administration achieves a faster and deeper response in Chinese patients with newly-diagnosed multiple myeloma. Micro-Abstract This retrospective investigation compared the efficacy and safety of bortezomib administration via subcutaneous and intravenous dosing in 307 patients with newly diagnosed multiple myeloma from a single Chinese center. Subcutaneous bortezomib is associated with better tolerance. However, intravenous administration achieves a faster and deeper response in these patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Clinical Trials | Conferences | Databases & Libraries | Hematology | Leukemia | Lymphoma | Myeloma